Achieving blood pressure control in clinical practice

Journal of the American Society of Hypertension

Volumn 2, Issue 4 SUPPL., 2008, Pages

  Williams, Bryan ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Blood pressure lowering; hypertension guidelines; PRISMA I; renin angiotensin system

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; NIFEDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MONOTHERAPY; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; TREATMENT PLANNING;

EID: 47049131217     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.03.009     Document Type: Article

References (19)

1. Ogden L.G., He J., Lydick E., and Whelton P.K. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 35 (2000) 539-543
2. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (2003) 2560-2572
3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
4. Sipahi I., Tuzcu M., Schoenhagen P., Wolski K.E., Nicholls S.J., Balog C., et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 48 (2006) 833-838
5. Mancia G., and Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20 (2002) 1461-1464
6. Arima H., Tzourio C., Butcher K., Anderson C., Bousser M.G., Lees K.R., et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke 37 (2006) 1497-1502
7. Williams B. Hypertension in the young: preventing the evolution of disease versus prevention of clinical events. J Am Coll Cardiol 50 (2007) 840-842
8. Neaton J.D., Grimm Jr. R.H., Prineas R.J., Stamler J., Grandits G.A., Elmer P.J., et al. Treatment of Mild Hypertension study final results. JAMA 270 (1993) 713-724
9. Conlin P.R., Spence J.D., Williams B., Ribeiro A.B., Saito I., Benedict C., et al. Angiotensin II antagonists for hypertension: are there differences in efficacy?. Am J Hypertens 13 (2000) 418-426
10. Sharma A.M., Davidson J.A., Gavin III J.R., and Desousa N.J. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 46 (2005) 898-899
11. Sharma A.M., Davidson J., Koval S., Lacourciere Y., and SMOOTH Study Investigators. Telmisartan/HCTZ versus valsartan/HCTZ in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 6 (2007) 28
12. NICE/BHS. Clinical guideline 34: hypertension. Management of hypertension in adults in primary care: partial update. http://www.nice.org.uk/CG034guidance Accessed: September 26, 2007
13. Williams B. β-blockers and the treatment of hypertension. J Hypertens 25 (2007) 1351-1353
14. Williams B. The obese hypertensive. The weight of evidence against β-blockers. Circulation 115 (2007) 1973-1974
15. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol 42 (2005) S50-S56
16. Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment study in ACE INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148 (2004) 52-61
17. Ruilope L.M., Redon J., and Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both?. Expectations from the ONTARGET trial programme. Vasc Health Risk Manag 3 (2007) 9
18. Williams B., Gosse P., Lowe L., Harper R., and PRISMA I Study Group. The prospective, randomized, investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 24 (2006) 193-200
19. Burke T.A., Sturkenboom M.C., Lu S.E., Wentworth C.E., Lin Y., and Rhoads G.G. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 24 (2006) 1193-1200